AU2001238499A1 - Nitroacridine/tumor inhibitor compositions - Google Patents

Nitroacridine/tumor inhibitor compositions

Info

Publication number
AU2001238499A1
AU2001238499A1 AU2001238499A AU3849901A AU2001238499A1 AU 2001238499 A1 AU2001238499 A1 AU 2001238499A1 AU 2001238499 A AU2001238499 A AU 2001238499A AU 3849901 A AU3849901 A AU 3849901A AU 2001238499 A1 AU2001238499 A1 AU 2001238499A1
Authority
AU
Australia
Prior art keywords
nitroacridine
tumor inhibitor
inhibitor compositions
compositions
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238499A
Other languages
English (en)
Inventor
Jerzy Kazimierz Konopa
Daniel Miller
Tiwari Raj
Barbara Wysocka-Skrzela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Medical College
Original Assignee
New York Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College filed Critical New York Medical College
Publication of AU2001238499A1 publication Critical patent/AU2001238499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001238499A 2000-02-18 2001-02-16 Nitroacridine/tumor inhibitor compositions Abandoned AU2001238499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18352900P 2000-02-18 2000-02-18
US60183529 2000-02-18
PCT/US2001/005276 WO2001060351A2 (fr) 2000-02-18 2001-02-16 Compositions inhibitrices de tumeurs a base de 1-nitroacridine

Publications (1)

Publication Number Publication Date
AU2001238499A1 true AU2001238499A1 (en) 2001-08-27

Family

ID=22673188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238499A Abandoned AU2001238499A1 (en) 2000-02-18 2001-02-16 Nitroacridine/tumor inhibitor compositions

Country Status (13)

Country Link
US (1) US7622478B2 (fr)
EP (1) EP1261325B1 (fr)
AT (1) ATE480237T1 (fr)
AU (1) AU2001238499A1 (fr)
CA (1) CA2400403C (fr)
CY (1) CY1111289T1 (fr)
DE (1) DE60143023D1 (fr)
DK (1) DK1261325T3 (fr)
ES (1) ES2352175T3 (fr)
IL (2) IL150978A0 (fr)
MX (1) MXPA02008014A (fr)
PT (1) PT1261325E (fr)
WO (1) WO2001060351A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US8647627B2 (en) * 2011-01-13 2014-02-11 Oncbiomune, L.L.C. Composition for a cancer vaccine
US20230286919A1 (en) * 2020-04-01 2023-09-14 Vestlandets Innovasjonsselskap As Isoquinoline derivatives for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694447A (en) 1970-03-10 1972-09-26 Smith Kline French Lab Complexes of phosphanilic acid and 9-amino-3-nitroacridine
PL106752B1 (pl) 1976-02-25 1980-01-31 Politechnika Gdanska Sposob otrzymywania nowych 1-nitro-9-alkiloaminoalkiloaminoakrydyn lub ich soli
PL126407B1 (en) 1980-04-23 1983-07-30 Politechnika Gdanska Process for preparing 1-nitro-9-hydroxyalkylaminoacridines or their salts
NZ200715A (en) 1982-05-24 1986-06-11 New Zealand Dev Finance Acridine derivatives and pharmaceutical compositions containing such
US4985436A (en) 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
HUT68856A (en) 1991-01-11 1995-08-28 Glaxo Lab Sa Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
JPH05331070A (ja) * 1992-02-07 1993-12-14 Takeda Chem Ind Ltd Ｔｎｐとインターロイキンとを含有してなる抗腫瘍剤
US5696131A (en) 1993-01-22 1997-12-09 Xenova Limited Treatment of cancers
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
EP0757559A4 (fr) 1994-04-29 1999-06-23 Molecular Medicine Center Composition destinee a l'apport de radio-isotopes toxiques au noyau de la cellule, et son utilisation
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5529989A (en) 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
KR0160110B1 (ko) 1995-05-24 1998-12-01 한영복 항암제 조성물
CA2303401A1 (fr) * 1997-10-01 1999-04-08 G.D. Searle & Co. Proteines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement anti-tumeur
US6943194B1 (en) 1998-01-09 2005-09-13 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
JP2002537262A (ja) * 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法

Also Published As

Publication number Publication date
EP1261325B1 (fr) 2010-09-08
CA2400403A1 (fr) 2001-08-23
DK1261325T3 (da) 2010-12-20
WO2001060351A3 (fr) 2002-01-24
CY1111289T1 (el) 2015-08-05
DE60143023D1 (de) 2010-10-21
MXPA02008014A (es) 2004-04-05
WO2001060351A2 (fr) 2001-08-23
ES2352175T3 (es) 2011-02-16
PT1261325E (pt) 2010-12-10
CA2400403C (fr) 2011-07-19
US7622478B2 (en) 2009-11-24
EP1261325A2 (fr) 2002-12-04
US20020037831A1 (en) 2002-03-28
ATE480237T1 (de) 2010-09-15
IL150978A (en) 2010-06-30
IL150978A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
WO2002022576A3 (fr) Indoles substitues en 3 inhibiteurs de l'angiogenese et de la proliferation cellulaire
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2000004954A3 (fr) Nouveaux inhibiteurs d'urokinase
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
WO2004030620A3 (fr) Inhibiteurs de tyrosine kinase
WO2004058153A9 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 3922
WO2002030465A3 (fr) Compositions inhibant la proliferation de cellules cancereuses
WO2003039545A3 (fr) Utilisation d'inhibiteurs de i$g(k)b kinase pour traiter le cancer
WO2003084475A3 (fr) Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
GB2378948B (en) Novel compounds for modulating cell proliferation
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
AU2002241720A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
MXPA03004879A (es) Inhibidores de farnesiltransferasa.
WO2002020000A3 (fr) Blocage d'oestrogene du sein combine au moyen d'exemestane et de raloxifene
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
WO2002032429A3 (fr) Inhibition de la dependance des cellules tumorales par rapport au facteur de croissance
WO2005032595A3 (fr) Procedes et compositions d'inhibition de stat5 dans des cellules cancereuses de la prostate
WO2001053524A3 (fr) Genes associes au cancer et leurs produits
WO2003077874A3 (fr) Composes tetrahydroisoquinoleine substitues, procedes de preparation et utilisation de ceux-ci
AU2003236701A1 (en) Guanidino phenylalanin compounds used as urokinase inhibitors